Skip to main content
SpringerLink
Log in

Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity

  • Original Articles
  • Fluosol-DA, Etoposide, BCNU, cis-Diamminedichloroplatinum (II), Solid Tumor, Fibrosarcoma
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The tumor growth delay produced by the combination of etoposide with the alkylating agent CDDP or BCNU and Fluosol-DA with carbogen breathing in three model tumor systems was examined. The addition of Fluosol-DA to etoposide treatment increased tumor growth delay 2.8-fold, 3.3-fold and 2.2-fold in the FSaIIC fibrosarcoma, the Lewis lung carcinoma and the SW2 small-cell xenograft, respectively. In both the FSaIIC fibrosarcoma and the Lewis lung carcinoma the combination of etoposide treatment with CDDP produced an additive effect. When Fluosol-DA was added to this combination the tumor growth delay increased 1.9-fold and 1.4-fold in the FSaIIC fibrosarcoma and the Lewis lung carcinoma, respectively. Adding Fluosol-DA to a treatment regimen with etoposide and BCNU produced a 2.2-fold, 2.0-fold and 1.6-fold increase in the tumor growth delay of the FSaIIC fibrosarcoma, the Lewis lung carcinoma and the SW2 small-cell xenograft, respectively. The effect of these various treatment combinations on tumor cell survival was assessed in the FSaIIC fibrosarcoma. When the alkylating agents CDDP or BCNU were prepared in Fluosol-DA, there was an additional increase in tumor cell kill, so that with CDDP there was 2.1-fold and 4.7-fold increase in tumor cell kill and with BCNU there was 1.5-fold and 1.2-fold increase in tumor cell kill compared to the drug plus Fluosol-DA and the drug plus Fluosol-DA/carbogen breathing, respectively. The combination of etoposide and CDDP led to less than additive cell killing, and the combination of etoposide and BCNU appeared to be additive, as predicted by simple product summation, in all of the treatment conditions examined. Both etoposide + CDDP and etoposide + BCNU produced additive or less than additive toxicity to bone marrow as measured by CFU-GM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Anderson G, Payne H (1985) Response rates and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the lung cancer treatment study group. Semin Oncol 12 [Suppl 2]: 21–22

    Google Scholar 

  2. Arnold AM, Whitehouse JM (1982) Interaction of VP-16-213 with the DNA repair antagonist chloroquine. Cancer Chemother Pharmacol 7: 123–126

    Google Scholar 

  3. Banham S, Dorwand A, Hutcheon A, Ahmedzai S, Cunningham D, Burnett A, Soukop M, Lucie N, Kaye S (1985) The role of VP-16 in the treatment of small cell lung cancer: studies of the West of Scotland lung cancer group. Semin Oncol 12 [Suppl 2]: 2–6

    Google Scholar 

  4. Bradley TR, Sumner MA (1969) Stimulation of mouse bone marrow colony growth in vitro by conditioned medium. Aust J Exp Biol Med Sci 46: 607–618

    Google Scholar 

  5. Cullen MH, Latief TN, Spooner D, Mould JJ, Chetiyawaraana AD (1985) Cisplatin, etoposide and radiotherapy in regional inoperable squamous cell carcinoma of the bronchus. Semin Oncol 12 [Suppl 2]: 14–16

    Google Scholar 

  6. Geyer R (1975) Review of perfluorochemical-type blood substitutes. In: Proceedings of the 10th International Congress for Nutrition: symposium on perfluorochemical artificial blood. Elsevier, Kyoto, pp 3–19

    Google Scholar 

  7. Geyer R (1978) Substitutes for blood and its components. In: Jamieson GA, Greenwalt TJ (eds) Blood substitutes and plasma expanders. Liss, New York, pp 1–21

    Google Scholar 

  8. Geyer R (1982) Oxygen transport in vivo by means of perfluorochemical preparations. N Engl J Med 307: 304–306

    Google Scholar 

  9. Greco FA, Johnson DH, Hande KR, Porter LL, Hainsworth JD, Wolff SN (1985) High-dose etoposide (VP-16) in small cell lung cancer. Semin Oncol 12 [Suppl 2]: 42–44

    Google Scholar 

  10. Hainsworth JD, Porter LL III, Johnson DH, Hande KR, Wolff SN, Birch R, Enas G, Greco FA (1986) Combination chemotherapy with vindesine, etoposide and cisplatin in nonsmall cell lung cancer: a pilot study of the Southeastern cancer study group. Cancer Treat Rep 70: 339–341

    Google Scholar 

  11. Issell BF, Muggia FM, Carter SF (eds) (1984) Etoposide (VP-16): current status and new developments. Academic, New York

    Google Scholar 

  12. Kalwinsky DK, Look AT, Ducore J, Fridland A (1983) Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 43: 1592–1597

    Google Scholar 

  13. Klastersky J (1985) VP-16 and cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 12 [Suppl 2]: 17–20

    Google Scholar 

  14. Loike JD, Horwitz SB (1976) Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15:5443–5448

    Google Scholar 

  15. Long BH, Minocha A (1983) Inhibition of topoisomerase II by VP-16-213(etoposide), VM-26 (teniposide) and structured congeners as an explanation for in vivo DNA breakage and cytotoxicity. Proc Am Assoc Cancer Res 24: 1271

    Google Scholar 

  16. Long BH, Musial ST, Brattain MG (1984) Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP-16-213 and VM-26: a quantitative structure-activity relationship. Biochemistry 23: 1183–1188

    Google Scholar 

  17. Mabel JA (1979) Therapeutic synergism in murine tumors for combinations of cis-diamminedichloroplatinum with VP-16 or BCNU. Proc Am Assoc Cancer Res 20: 230

    Google Scholar 

  18. Mason KA, Withers HR, Steckel RJ (1984) Acute effects of a perfluorochemical oxygen carrier on normal tissues of the mouse. Radiat Res 104: 387–394

    Google Scholar 

  19. Meyer TJ, Pearlman NW, Siebert PE, Murphy JR, White MJ, Zaloznik A, Braun T, Rempel P (1986) Comparison of alternating to non-alternating chemotherapy regimens for nonsmall cell lung cancer. Cancer Treat Reps 70: 711–714

    Google Scholar 

  20. Natale RB, Wittes RE (1985) Alternating combination chemotherapy regimens in small cell lung cancer. Semin Oncol 12 [Suppl 2]: 7–13

    Google Scholar 

  21. Pike BL, Robinson WA (1970) Human bone marrow colony growth in agar-gel. J Cell Physiol 76: 77–84

    Google Scholar 

  22. Pommier Y, Schwartz RE, Zwelling LA, Kerrigan D, Mattern MR, Charcosset JY, Jacquemin-Sablon A, Kohn KW (1986) Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 611–616

    Google Scholar 

  23. Rice L, Urano M, Siut HD (1980) The radiosensitivity of a murine fibrosarcoma as measured by three cell survival assays. Br J Cancer 41 [Suppl 4]: 240–244

    Google Scholar 

  24. Rockwell S (1985) Use of a perfluorochemical emulsion to improve oxygenation in a solid tumor. Int J Radiat Oncol Biol Phys 11: 97–103

    Google Scholar 

  25. Rockwell S, Mate TP, Irvin CG, Nierenburg M (1986) Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion. Int J Radiat Oncol Biol Phys 12: 1315–1318

    Google Scholar 

  26. Rose C, Lustig R, McIntosh N, Teicher B (1986) A clinical trial of Fluosol-DA in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 12: 1325–1327

    Google Scholar 

  27. Ross WE (1985) DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 34: 4191–4195

    Google Scholar 

  28. Shipley WV, Stanley JA, Steel GG (1975) Tumor size dependence in the radiation response of the Lewis lung carcinoma. Cancer Res 35: 2488–2493

    Google Scholar 

  29. Stahel RA, Speak JA, Bernal SD (1985) Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human small cell carcinoma and squamous cell carcinomas.Int J Cancer 35: 11–17

    Google Scholar 

  30. Stanley JA, Shipley WA, Steel GG (1977), Influence of tumor size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumor. Br J Cancer 36: 105–113

    Google Scholar 

  31. Steel GG, Nill RP, Peckham MJ (1978) Combined radiotherapy-chemotherapy of Lewis lung carcinoma. Int J Radiat Oncol Biol Phys 4: 49–52

    Google Scholar 

  32. Teicher BA, Rose CM (1984a) Perfluorocheical emulsion can increase tumor radiosensitivity. Science 223: 934–936

    Google Scholar 

  33. Teicher BA, Rose CM (1984b) Sensitization of solid mouse tumor to x-ray treatment by oxygen-carrying perfluorochemical emulsion.Cancer Res 44: 4285–4288

    Google Scholar 

  34. Teicher BA, Rose CM (1986) Effect of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA. Int J Radiat Oncol Biol Phys 12: 1311–1313

    Google Scholar 

  35. Teicher BA, Holden SA, Rose CM (1985) Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J Natl Cancer Inst 75: 1129–1133

    Google Scholar 

  36. Teicher BA, Holden SA, Rose CM (1986) Effect of Fluosol-DA/O2 tumor cell and bone marrow cytotoxicity of nitrosoureas in mice bearing FSaIIC fibrosarcoma. Int J Cancer 38: 285–288

    Google Scholar 

  37. Van Maanen JMS, Holthuis JJ, Gobas F, de Vries J, van Oort WJ, Emmelot P, Pinedo HM (1983) Role of bioactivation in covalent binding of VP-16 to rat liver and HeLa cell microsomal proteins. Proc Am Assoc Cancer Res 24:319

    Google Scholar 

  38. Wozniak AJ, Ross WE (1983) DNA damage as a basis for 4′-dimethylepipo-dophyllotoxin-9-(4,6-O-ethylidene-β-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res 43: 120–124

    Google Scholar 

  39. Wozniak AJ, Glisson BS, Hande KR, Ross WE (1984) Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res 44: 626–632

    Google Scholar 

  40. Yalowich JC, Ross WE (1984) Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res 44: 3360–3365

    Google Scholar 

  41. Zhang WL, Pence D, Patten M, Levitt SH, Song CW (1984) Enhancement of tumor response to radiation by Fluosol-DA. Int J Radiat Oncol Biol Phys10 [Suppl 2]: 172–175

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, 44 Binney Street, 02115, Boston, MA, USA

    Beverly A. Teicher, Samuel D. Bernal, Sylvia A. Holden & Kathleen N. S. Cathcart

Authors
  1. Beverly A. Teicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel D. Bernal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvia A. Holden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathleen N. S. Cathcart
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by NCI grant # 2PQ1-CA19589-10 (BAT), RO1-CA36498-03 (SDB), grants from the American Cancer Society of New York (CH 340) and Alpha Therapeutics Co., Los Angeles,CA 90032 (BAT) and NIH fellowship # 5F32-CA07821-02 (SAH)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teicher, B.A., Bernal, S.D., Holden, S.A. et al. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity. Cancer Chemother. Pharmacol. 21, 281–285 (1988). https://doi.org/10.1007/BF00264192

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00264192

Keywords

Search

Navigation